Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes

This multicenter randomized trial investigated whether hybrid closed loop insulin therapy could preserve residual C peptide secretion in youths with new onset type 1 diabetes compared to standard insulin therapy over 24 months. Despite improved glycemic control in the closed loop group (mean HbA1c 1.0% lower at 24 months), no significant difference in C peptide preservation was observed between groups. The study highlights the challenges of halting beta cell decline but underscores the efficacy of closed loop systems in maintaining tighter glucose control.

This multicenter randomized trial investigated whether hybrid closed loop insulin therapy could preserve residual C peptide secretion in youths with new onset type 1 diabetes compared to standard insulin therapy over 24 months. Despite improved glycemic control in the closed loop group (mean HbA1c 1.0% lower at 24 months), no significant difference in C peptide preservation was observed between groups. The study highlights the challenges of halting beta cell decline but underscores the efficacy of closed loop systems in maintaining tighter glucose control.